Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
ARTW Art's Way Manufacturing Co Inc

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-0.2236 (-9.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 168,637 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.


Macy's, Inc. Provides Fourth Quarter 2022 Update Ahead of the ICR Conference

4:15 pm ET January 6, 2023 (BusinessWire) Print

Macy's, Inc. (NYSE: M) today announced updates to its fiscal fourth quarter sales and adjusted EPS guidance provided on its November 17, 2022 earnings call. Net sales are now expected to be at the low-end to mid-point of the previously issued range of $8,161 to $8,401 million while adjusted diluted earnings per share are expected to be in the previously issued range of $1.47 to $1.67. On a percentage basis, total end-of-quarter inventories are on track to be slightly below last year and down mid-teens relative to 2019.

"Our teams executed well during a competitive holiday season. In an environment when discretionary spending was under pressure, we operated with precision and agility," said Jeff Gennette, chairman and chief executive officer of Macy's, Inc. "Black Friday/Cyber Monday sales were in line with our expectations, while the week leading up to and following Christmas were ahead. However, the lulls of the non-peak holiday weeks were deeper than anticipated. Overall, our occasion apparel and gift-giving business were strengths and inventory composition and price points aligned with customers' needs. Throughout the season, Bloomingdale's and Bluemercury continued to outperform. Across nameplates, we stayed close to our customer, utilizing data and analytics tools to respond to shifts in demand. This has contributed to clean inventories and an expected gross margin rate roughly in line with previously issued fourth quarter guidance."

"Based on current macro-economic indicators and our proprietary credit card data, we believe the consumer will continue to be pressured in 2023, particularly in the first half, and have planned inventory mix and depth of initial buys accordingly. We take a balanced approach to merchandise receipts and remain committed to offering fashion and value across nameplates and channels, with the capacity to adjust in-season buys and chase into areas of strength. As we look further ahead, the efficiencies we've built into our business coupled with our financial health, data-driven decision processes, and agile ways of working, allow us to operate from a position of strength while continuing to invest in our future," Gennette continued.

Jeff Gennette, chairman and chief executive officer, Adrian Mitchell, chief financial officer, and Nata Dvir, Macy's chief merchandising officer, will be participating in the 2023 ICR Conference in Orlando, FL. The company is scheduled to hold meetings beginning Sunday, January 8, 2023, and is scheduled to present at 9 a.m. ET on Monday, January 9, 2023. A live webcast of the event will be available on the investor relations section of the Macy's, Inc. website at A recording of the webcast will be available on the same website for 90 days following the event.

The company expects to report full results for the fourth quarter and fiscal year 2022 in early March 2023.

About Macy's, Inc.

At Macy's, Inc. (NYSE: M), we are a trusted source for quality brands at great value from off-price to luxury. Across our iconic nameplates, including Macy's, Bloomingdale's, and Bluemercury, we help our customers express their unique style and celebrate special moments, big and small. Headquartered in New York City, we operate one of retail's largest e-commerce businesses integrated with a nationwide footprint to deliver the most convenient and seamless shopping experience. Our purpose is to create a brighter future with bold representation - so we can realize the full potential of everyone of us. For more information, visit

View source version on

SOURCE: Macy's, Inc.

Media - Chris Grams 

Investors - Pamela Quintiliano
comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.